Is Benitec Biopharma Inc. (BNTC) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 25.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 25.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.9% / 33% | 98.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 25.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.9% / 33% | 98.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -33.5% | |
| Return on Assets (ROA) | -22.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$24M |
| Free Cash Flow | -$24M |
| Total Debt | $849,000 |
| Debt-to-Equity | 0.5 |
| Current Ratio | 67.7 |
| Total Assets | $100M |
Price & Trading
| Last Close | $10.81 |
| 50-Day MA | $11.53 |
| 200-Day MA | $12.88 |
| Avg Volume | 174K |
| Beta | 0.1 |
|
52-Week Range
$9.85
| |
About Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Benitec Biopharma Inc. (BNTC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Benitec Biopharma Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Benitec Biopharma Inc.'s debt ratio?
Benitec Biopharma Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are Benitec Biopharma Inc.'s key financial metrics?
Benitec Biopharma Inc. has a market capitalization of $352M. Return on equity stands at -33.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.